| (Values in U.S. Thousands) | Sep, 2025 | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | -100.00% |
| Net Income | -7,190 | -6,170 | -8,370 | -17,550 | -13,340 |
| Net Income Growth | -16.53% | +26.28% | +52.31% | -31.56% | -109.75% |
Edesa Biotech Inc (EDSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Edesa Biotech Inc. is a biopharmaceutical company. It is focused on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company's product pipeline consists of EB01, EB02 and EB04 which are in clinical stage. Edesa Biotech Inc., formerly known as Stellar Biotechnologies Inc., is based in TORONTO.
Fiscal Year End Date: 09/30